Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 5/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL355415 | 1.00 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL353346 | 1.00 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL76796 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL29783468 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL196338 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL700933 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Methyl Alcohol SCHEMBL28477033 | 0.95 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Bromide SCHEMBL28031435 | 0.95 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Alcohol SCHEMBL28297686 | 0.94 | SLC7A5 (0.48) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL1532654 | 0.93 | SLC7A5 (0.52) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504883-A | Synthesis method of RNA monomer intermediate 2' -fluoro-nucleoside modifier | 安徽信佰生物医药科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119409588-A | Caffeoyl amino acid methyl ester derivative and preparation method and application thereof | 西北大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119241617-A | 2 '-Deoxy-2' -fluoro-N4-substituted cytidine compound, preparation method and application thereof | 河南省科学院高新技术研究中心 | 2025-01-03 | — | — | CN | claimed |
| CN-114983852-B | Anti-aging cosmetic with whitening and moisturizing effects and preparation method thereof | 中科重生(雄安)生物科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118662369-A | Crease-resistant skin care composition containing organic nitrate and preparation method thereof | 瑞思益特(江西)生物科技开发有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118078964-B | Recombinant human interferon ointment and its preparation method | 长春生物制品研究所有限责任公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118078964-A | Recombinant human interferon ointment and its preparation method | 长春生物制品研究所有限责任公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118001199-A | Anti-oxidation and skin tightening essence containing tri-factor tripeptide and preparation method thereof | 中科润航健康科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117946007-A | Curcumin-amino acid methyl ester derivative and preparation method and application thereof | 河北科技大学 | 2024-04-30 | — | — | CN | claimed |
| CN-117462561-A | Minocycline-containing composition for treating acne and preparation method thereof | 广州仁恒医药科技股份有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | claimed |
| EP-1155001-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2003-05-28 | — | — | EP | claimed |
| US-6417195-B1 | LIBRARIES AND COMBINATORIAL CHEMISTRY | LION BIOSCIENCE AG (DE) | 2002-07-09 | — | — | US | claimed |
| EP-1155001-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-0397652-B1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORP (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0397652-A4 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | — | 1991-04-03 | — | — | EP | claimed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | claimed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | DCK, DHPS, DHX15 | SLC7A5 2015/4885ANPEP 1411/4885RNPEP 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.